MARIMED INC.
MRMD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MRMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$27.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2026.
Run MARIMED INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MARIMED INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
OCF $949K · Net income -$4M · Debt/OCF 20.5×
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
4 buys · 0 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$7
| Holder | Shares | Value |
|---|---|---|
| game plan financial advisors, llc | 100 | $7 |
Governance
Frequently asked questions
Who is the CEO of MARIMED INC.?
Mr. Jon R. Levine is the chief executive officer of MARIMED INC. (MRMD).
Where is MARIMED INC. headquartered?
MARIMED INC. (MRMD) is headquartered in Norwood, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.